National Toxicology Program (NTP) Finds Cell Phone Radiation Causes Cancer
Peer-reviewed comments on NTP cellphone radiation study by Hardell and Carlberg
Sep 24, 2018
by Ronald Melnick, Former NTP Director of Special Programs
Sep 6, 2018
Videos of NTP Peer Review Meeting
Experts Find "Clear Evidence" of Cancer from Cell Phone Radiation in NTP Study
March 28, 2018 (Last updated April 10)
Eleven experts convened by the National Toxicology Program (NTP) over a three day period to review the draft technical reports from the NTP's cell phone radiation studies concluded that there is "clear evidence" that exposure to cell phone radiation caused a rare cancer in the hearts of male rats, and "there is equivocal evidence" in the hearts of female rats.
The expert panel also reported "some evidence" that cell phone radiation exposure caused brain cancer in male and female rats and cancer of the adrenal glands in male rats.
Additionally, "equivocal evidence" of cancer risk was reported in the pituitary, adrenal, and prostate glands and pancreas and liver in male rats and adrenal glands in female rats.
The mice in the study, exposed to a different cell phone radiation frequency than the rats (1800 MHz vs. 900 MHz), displayed less evidence of cancer risk. Equivocal evidence of cancer risk from cell phone radiation was reported for lymphoma in male and female mice. Equivocal evidence was also reported for skin, lung, and liver cancer in male mice.
In seven instances, the expert group upgraded the evaluations of evidence published by NTP staff in the draft technical reports. Thus, the NTP scientists appear to have been overly conservative in their assessment of the hazards of long-term exposure to cell phone radiation. According to a former NTP scientist, "There was never a time when so many upgrades were recommended."
The following table based upon NTP's official summary of actions compares the evaluations of evidence of carcinogenicity prepared by NTP staff with the expert committee's findings. The two-page document which also contains the committee's findings for nonneoplastic lesions can be be downloaded from http://bit.ly/NTP180330.
The presentations and oral public comments are available at the following link: http://bit.ly/2qmvtQg.
Clear Evidence of Carcinogenic Activity is demonstrated by studies that are interpreted as showing a dose-related (i) increase of malignant neoplasms, (ii) increase of a combination of malignant and benign neoplasms, or (iii) marked increase of benign neoplasms if there is an indication from this or other studies of the ability of such tumors to progress to malignancy.
Some Evidence of Carcinogenic Activity is demonstrated by studies that are interpreted as showing a chemical-related increased incidence of neoplasms (malignant, benign, or combined) in which the strength of the response is less than that required for clear evidence.
Equivocal Evidence of Carcinogenic Activity is demonstrated by studies that are interpreted as showing a marginal increase of neoplasms that may be chemically related.
No Evidence of Carcinogenic Activity is demonstrated by studies that are interpreted as showing no chemical-related increases in malignant or benign neoplasms.
Note: Although the definitions typically are applied to chemical agents, NTP also uses them with physical agents like cell phone radiation.
PDF of document also includes nonneoplastic results & definitions: http://bit.ly/NTP180330
March 16, 2018 (Updated March 25)
To view webcast of NTP review meeting on March 26-28 from 8:30 AM - 5:00 PM EDT:
The National Toxicology Program (NTP) requested public comments about the two draft NTP Technical Reports on Cell Phone Radiofrequency Radiation. Due to a lag between when comments were submitted and posted to the NTP website, below are links to selected comments from scientists and environmental health organizations about the reports.
Public Comments: Scientists
George Carlo, PhD, The Science and Public Policy Institute
C.K. Chou, PhD, CK Chou Consulting
Lennart Hardell, MD, PhD, Michael Carlberg, MSc, University Hospital, Örebro, Sweden; Lena Hedendahl, MD, The Environment and Cancer Research Foundation
Magda Havas, PhD, Trent University
Ronald Kostoff, PhD
Ronald Melnick, PhD, Retired Senior Toxicologist, National Toxicology Program
Joel Moskowitz, PhD, University of California, Berkeley
Cindy Russell, MD, Physicians for Safe Technology
Annie J. Sasco, MD, DrPH, SM, MPH, retired Director of Research,INSERM (French NIH); former Unit Chief, IARC-WHO
Public Comments: Organizations
Association Alerte Phonegate (Dr. Marc Arazi)
EMF Research Committee, Korean Institute of Electromagnetic Engineering and Science (KIEES), South Korea
Environmental Health Trust
Environmental Working Group
Brief History of NTP Cell Phone Radiation Studies and Comments on Reports
Ramazzini Institute Cell Phone Radiation Study Replicates NTP Study
The members of the two peer review committees for the NTP meeting have been announced.
David Eaton, PhD, University of Washington, Chair
Technical Panel 1: Reverberation Chamber Exposure System: Assess the reverberation chamber technology for evaluating the effects of cell phone radiofrequency radiation exposure in rats and mice.
Frank Barnes, PhD, University of Colorado Boulder
Asimini Kiourti, PhD, Ohio State University
James Lin, PhD, University of Illinois at Chicago
Technical Panel 2: NTP Findings in Rats and Mice: (1) Review and evaluate the scientific and technical elements of the study and its presentation; (2) Determine whether the study’s experimental design, conduct, and findings support the NTP’s conclusions regarding the carcinogenic activity and toxicity of the test agent.
Rick Adler, DVM, PhD, DACVP, Glaxo Smith Kline
Lydia Andrews-Jones, DVM, PhD, DACVP, Allergan, Inc,
J. Mark Cline, DVM, PhD, DACVP, Wake Forest School of Medicine
George Corcoran, PhD, ATS, Wayne State University
Susan Felter, PhD, Proctor & Gamble
Jack Harkema, DVM, PhD, DACVP, Michigan State University
Wolfgang Kaufmann, DVM, PhD, DECVP, Fellow IATP, Merck (retired)
Tyler Malys, PhD, National Cancer Institute
Kamala Pant, MS, BioReliance
Matthias Rinke, DVM, PhD, FTA Pathology, CVP, Fellow IATP, Bayer Pharma (retired)
Laurence Whiteley, DVM, PhD, DACVP, Pfizer
Jan 29, 2018 (Updated Jan 31, 2018)
The following information was excerpted from the Federal Register.
NTP panels are technical, scientific advisory bodies to provide independent scientific peer review. These panels help ensure transparent, unbiased, and scientifically rigorous input to the program. Scientists interested in serving on an NTP panel should provide their current curriculum vitae to Canden Byrd by email: NTP-Meetings@icf.com.